Comparison of Two Early Treatments for Premature Babies and Their Effects Over Time (PREMOTSENS)
Comparison of the Impact of Two Early Interventions on the Development of Premature Infants: a Clinical Study of Short- and Long-term Effects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Bellardie
- Phone Number: +33 6 59 68 51 43
- Email: manon.bellardie@univ-amu.fr
Study Locations
-
-
-
Marseille, France
- Hôpital Saint-Joseph
-
Contact:
- Bellardie
- Phone Number: +33 6 59 68 51 43
- Email: manon.bellardie@univ-amu.fr
-
Marseille, France
- Clinique Bouchard
-
Contact:
- Bellardie
- Phone Number: +33 6 59 68 51 43
- Email: manon.bellardie@univ-amu.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- For premature infants: birth between 30 and 34 weeks of gestation plus 6 days, and weighing more than 1800 g at the start of the trial.
- For full-term infants: pregnancy and birth without complications at or after 37 weeks of gestation, with an Apgar score ≥7 at 10 minutes after birth.
For parents or legal guardians:
- Parents over the age of 18
- Parent agreeing to be filmed with their infant (parent who will be responsible for the treatment)
- Parents capable of understanding the information document
- Parent affiliated with or beneficiary of the French social security system
- Parents who have been informed and have freely given their informed written consent no later than the day of inclusion.
Exclusion Criteria:
For premature infants:
- Birth before 30 weeks of gestation
- Weight less than 1800 g at the start of the trial
- Morbidities related to prematurity (necrotizing enterocolitis, cerebral parenchymal damage, stage III and IV intraventricular hemorrhages)
- Presence of a congenital malformation or chromosomal abnormality
- Known sensory, motor, or central nervous system impairment
- Patient receiving non-invasive ventilation at 34 weeks gestational age (CPAP and high-flow nasal cannula)
For full-term infants:
- Birth before 37 weeks gestation
- Birth with complications
For the parent providing the treatment and the infant:
- Presence of a known sensory, motor, or central nervous system impairment
- Presence of a congenital condition
- Presence of psychological distress in the parent
For both parents:
- Under guardianship, conservatorship, or legal protection
- Situation of extreme psychosocial instability and/or mention of domestic and/or intra-family violence
- Illicit drug or alcohol use by the mother during the perinatal period
- Participant is in another study with an ongoing exclusion period during inclusion
- Involuntary hospitalization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ATVV group
The experimental group comprising premature infants receiving ATVV care
|
ATVV consists in providing the infant with multisensory stimulation through massage, talking, eye contact, and gentle rocking.
|
|
Other: Parental Singing group
The intervention control group comprising premature infants receiving Parental Singing care
|
The singing intervention consists in parents singing softly next to the child's ear.
|
|
No Intervention: Control group
The control group comprising full-term infants
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Analysis of the long-term impact of ATVV care on premature infants
Time Frame: The primary endpoint will be measured at 6 months corrected age in premature infants, and at 6 months in full-term infants.
|
The primary objective is to analyze the long-term impact of ATVV care on premature infants.
Motor and cognitive development at 6 months will be compared between premature infants (30 to 34 weeks gestation) receiving ATVV care with premature infants receiving "Singing" care and full-term infants (>37 weeks gestation), using the Bayley Scales of Infant and Toddler Development, 4th Edition (from 16 days to 42 months) and its motor subscore (assessing fine and gross motor skills) and cognition subscore.
A subscore (standardized score) ≥ 85 out of 160 in each domain corresponds to typical development.
|
The primary endpoint will be measured at 6 months corrected age in premature infants, and at 6 months in full-term infants.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motor skills
Time Frame: The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
Three different motor skills will be measured: spontaneous motor skills, involving general movements and accelerometry (head/forearm/calf); voluntary motor skills, involving Crawliskate in the laboratory with a motion capture system; and oral motor skills, involving sucking a pacifier with a pressure sensor adapted for premature infants.
|
The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
|
Overall and communication development
Time Frame: The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
The outcome is measured using the subscore for the receptive and expressive communication scales, and the ensemble of communication, motor, and cognitive subscores, from the Bayley Scales of Infant and Toddler Development, 4th Edition.
A standardized score ≥ 85 out of 160 corresponds to typical development.
|
The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
|
Multisensory integration
Time Frame: The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
A visuo-vestibular conflict paradigm using a device that measures head acceleration of the infant.
|
The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
|
Level of alertness
Time Frame: The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
Alertness is evaluated on the Prechtl assessment scale, comprising 5 levels: quiet sleep; active/restless sleep; quiet wakefulness; restless wakefulness; and agitation.
|
The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
|
Precocious interactions
Time Frame: The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
The outcome is measured using a scale of mutual dyadic (parent-child) interactions from the Dyadic Mutuality Code (Censuello) that ranks 6 items as present or absent: mutual attention; positive affects; interactional turn-taking; maternal pauses; clarity of infant cues; and maternal sensitivity and responsiveness.
|
The outcome is measured between 34 weeks gestational age and 2 months of corrected age.
|
|
Parenting stress
Time Frame: The outcome is measured at 2 months of corrected age.
|
The outcome is evaluated according to the PSI-4-SF parenting stress index questionnaire, which divides 36 items into the following subscales: parenting stress; dysfunctional parent-child interaction; and difficult child.
Each item is rated from 1 (strongly disagree) to 5 (strongly agree), to determine whether parental stress is low, fair or elevated.
|
The outcome is measured at 2 months of corrected age.
|
|
Heart rate
Time Frame: The outcome measure will be provided by the parent from 34 weeks gestational age to term equivalent age.
|
Infants in the prenatal service are monitored for heart rate.
Heart rate values will be read by parents from the monitor screen, once per minute for five minutes.
The expected value for premature infants is between 130-170 beats per minutes.
|
The outcome measure will be provided by the parent from 34 weeks gestational age to term equivalent age.
|
|
Respiratory rate
Time Frame: The outcome measure will be provided by the parent from 34 weeks gestational age to term equivalent age.
|
Infants in the prenatal service are monitored for respiratory rate.
Respiratory rate will be read by parents from the monitor screen, once per minute for five minutes.
The expected value for premature infants is approximately 50 cycles/minute.
|
The outcome measure will be provided by the parent from 34 weeks gestational age to term equivalent age.
|
|
Oxygen saturation
Time Frame: The outcome measure will be provided by the parent from 34 weeks gestational age to term equivalent age.
|
Infants in the prenatal service are monitored for oxygen saturation.
Oxygen saturation will be read by parents from the monitor screen, once per minute for five minutes.
The expected value for premature infants is between 85-95%.
|
The outcome measure will be provided by the parent from 34 weeks gestational age to term equivalent age.
|
|
Weight
Time Frame: Weight will be recorded at 2 and 6 months corrected age.
|
Weight will be taken from medical records.
Weight gain (kg) will be monitored for each infant.
|
Weight will be recorded at 2 and 6 months corrected age.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PREMOTSENS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.